{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:45:11Z","timestamp":1792835111952,"version":"4.5.0"},"reference-count":11,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND AND OBJECTIVES:<\/jats:title>\n                    <jats:p>Palivizumab effectively prevents severe respiratory syncytial virus (RSV) disease in preterm infants. Our objective was to test whether palivizumab prophylaxis given to preterm infants during the first RSV season reduces the incidence of subsequent recurrent wheezing up to 3 years of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We conducted an observational prospective multicenter (52 registered hospitals in Japan) case-control study in preterm infants with a gestational age between 33 and 35 weeks followed for 3 years. During the 2007\u20132008 RSV season, the decision to administer palivizumab was made based on standard medical practice. In April 2008, 52 hospitals were recruited. Study participants were prospectively followed to the age of 3 years. Parents of study subjects reported the infants\u2019 physician\u2019s assessment of recurrent wheezing, used a report card and a novel mobile phone-based reporting system by using the Internet. The primary end point was the incidence of physician-diagnosed recurrent wheezing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Of 444 preterm infants enrolled, 349 received palivizumab during the first 6 months of life and 95 infants did not. Physician-diagnosed recurrent wheezing was observed in 6.4% and 18.9% of infants in the treated and untreated groups, respectively (P &amp;lt; .001). This difference remained significant after adjustment for known risk factors of recurrent wheezing (P &amp;lt; .001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Palivizumab prophylaxis administered to preterm infants 33 to 35 weeks\u2019 gestational age is associated with a significantly lower incidence of recurrent wheezing during the first 3 years of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1542\/peds.2013-0982","type":"journal-article","created":{"date-parts":[[2013,10,14]],"date-time":"2013-10-14T20:54:29Z","timestamp":1381784069000},"page":"811-818","source":"Crossref","is-referenced-by-count":134,"title":["Effect of Palivizumab Prophylaxis on Subsequent Recurrent Wheezing in Preterm Infants"],"prefix":"10.1542","volume":"132","author":[{"given":"Shigemi","family":"Yoshihara","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kusuda","sequence":"additional","affiliation":[{"name":"Maternal and Perinatal Center, Tokyo Women\u2019s Medical University, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Tokai University School of Medicine, Kanagawa, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Okada","sequence":"additional","affiliation":[{"name":"National Hospital Organization, Fukuoka National Hospital, Fukuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankei","family":"Nishima","sequence":"additional","affiliation":[{"name":"Fukuoka Jogakuin Nursing College, Fukuoka, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.F.","family":"Sim\u00f5es","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Infectious Diseases, University of Colorado School of Medicine, Children\u2019s Hospital Colorado, and the Center for Global Health, Colorado School of Public Health, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2013,11,1]]},"reference":[{"issue":"5","key":"2021120903024206700_B1","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1164\/ajrccm.161.5.9906076","article-title":"Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.","volume":"161","author":"Sigurs","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2021120903024206700_B2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.200406-730OC","article-title":"Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13.","volume":"171","author":"Sigurs","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"2021120903024206700_B3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/thx.2009.121582","article-title":"Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life.","volume":"65","author":"Sigurs","year":"2010","journal-title":"Thorax"},{"issue":"9178","key":"2021120903024206700_B4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(98)10321-5","article-title":"Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years.","volume":"354","author":"Stein","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"2021120903024206700_B5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/thx.2003.013391","article-title":"Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infection.","volume":"59","author":"Bont","year":"2004","journal-title":"Thorax"},{"issue":"5","key":"2021120903024206700_B6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1399-3038.2005.00298.x","article-title":"Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study.","volume":"16","author":"Henderson","year":"2005","journal-title":"Pediatr Allergy Immunol"},{"issue":"14","key":"2021120903024206700_B7","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.clinthera.2011.01.007","article-title":"Serious early childhood wheezing after respiratory syncytial virus lower respiratory tract illness in preterm infants.","volume":"32","author":"Romero","year":"2010","journal-title":"Clin Ther"},{"issue":"5","key":"2021120903024206700_B8","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.","volume":"176","author":"Johnson","year":"1997","journal-title":"J Infect Dis"},{"issue":"3 pt 1","key":"2021120903024206700_B9","first-page":"531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants.","volume":"102","year":"1998","journal-title":"Pediatrics"},{"issue":"1","key":"2021120903024206700_B10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jpeds.2007.02.032","article-title":"Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.","volume":"151","author":"Simoes","year":"2007","journal-title":"J Pediatr"},{"issue":"2","key":"2021120903024206700_B11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaci.2010.05.026","article-title":"The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children.","volume":"126","author":"Sim\u00f5es","year":"2010","journal-title":"J Allergy Clin Immunol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/132\/5\/811\/1098748\/peds_2013-0982.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/132\/5\/811\/1098748\/peds_2013-0982.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T11:39:42Z","timestamp":1639049982000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/132\/5\/811\/31706\/Effect-of-Palivizumab-Prophylaxis-on-Subsequent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,1]]},"references-count":11,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,11,1]]},"published-print":{"date-parts":[[2013,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2013-0982","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718144287.793486172","asserted-by":"object"}]},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,1]]}}}